Esperion Therapeutics Company Profile (NASDAQ:ESPR)

About Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics logoEsperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ESPR
  • CUSIP: N/A
  • Web: www.esperion.com
Capitalization:
  • Market Cap: $1.06 billion
  • Outstanding Shares: 22,590,000
Average Prices:
  • 50 Day Moving Avg: $43.30
  • 200 Day Moving Avg: $32.54
  • 52 Week Range: $9.40 - $50.52
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.82
  • P/E Growth: -0.78
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $8.52 per share
  • Price / Book: 5.50
Profitability:
  • EBIDTA: ($101,960,000.00)
  • Return on Equity: -42.81%
  • Return on Assets: -40.33%
Debt:
  • Current Ratio: 8.70%
  • Quick Ratio: 8.70%
Misc:
  • Average Volume: 659,708 shs.
  • Beta: 2.72
  • Short Ratio: 7.13
 
Frequently Asked Questions for Esperion Therapeutics (NASDAQ:ESPR)

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) posted its quarterly earnings data on Monday, May, 1st. The company reported ($1.80) EPS for the quarter, missing the Zacks' consensus estimate of ($1.44) by $0.36. During the same quarter in the previous year, the company posted ($0.65) EPS. View Esperion Therapeutics' Earnings History.

Where is Esperion Therapeutics' stock going? Where will Esperion Therapeutics' stock price be in 2017?

11 equities research analysts have issued 12-month price objectives for Esperion Therapeutics' stock. Their predictions range from $12.50 to $60.00. On average, they anticipate Esperion Therapeutics' share price to reach $40.95 in the next year. View Analyst Ratings for Esperion Therapeutics.

What are analysts saying about Esperion Therapeutics stock?

Here are some recent quotes from research analysts about Esperion Therapeutics stock:

  • 1. According to Zacks Investment Research, "Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. " (5/9/2017)
  • 2. Needham & Company LLC analysts commented, "The FDA has agreed that the Phase III CLEAR LDL program of bempedoic acid is sufficient to support approval. This resolves a long standing issue for ESPR shares regarding the ability to get their drug approved without a completed CVOT. This regulatory confirmation comes on the heals of the positive FOURIER outcomes data for Repatha and the genetic validation of the target for bempedoic acid which was presented yesterday at the American College for Cardiology (ACC). As a result of this trifecta of positive news we are increasing our price target on ESPR to $58 from $25. We once again model US approval based on CLEAR LDL in 2020." (3/20/2017)

Who are some of Esperion Therapeutics' key competitors?

Who are Esperion Therapeutics' key executives?

Esperion Therapeutics' management team includes the folowing people:

  • Timothy M. Mayleben, President, Chief Executive Officer, Director
  • Narendra D. Lalwani Ph.D., FAHA, DABT, Chief Operating Officer, Executive Vice President - Research & Development
  • Mary P. McGowan M.D., Chief Medical Officer
  • Nicole Vitullo MBA, Independent Lead Director
  • Roger S. Newton Ph.D., FAHA, FACN, Director
  • Scott N. Braunstein M.D., Independent Director
  • Dov A. Goldstein M.D., Independent Director
  • Antonio M. Gotto Jr., M.D., Ph.D., Independent Director

Who owns Esperion Therapeutics stock?

Esperion Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Meditor Group Ltd (2.51%), Peregrine Capital Management LLC (1.41%), Russell Investments Group Ltd. (0.10%), US Bancorp DE (0.04%), Aperio Group LLC (0.02%) and Creative Planning (0.01%). Company insiders that own Esperion Therapeutics stock include Dov A Md Goldstein, Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani and Timothy M Mayleben. View Institutional Ownership Trends for Esperion Therapeutics.

Who sold Esperion Therapeutics stock? Who is selling Esperion Therapeutics stock?

Esperion Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd. and Creative Planning. View Insider Buying and Selling for Esperion Therapeutics.

Who bought Esperion Therapeutics stock? Who is buying Esperion Therapeutics stock?

Esperion Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Meditor Group Ltd, Peregrine Capital Management LLC, Aperio Group LLC and US Bancorp DE. Company insiders that have bought Esperion Therapeutics stock in the last two years include Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani and Timothy M Mayleben. View Insider Buying and Selling for Esperion Therapeutics.

How do I buy Esperion Therapeutics stock?

Shares of Esperion Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Esperion Therapeutics' stock price today?

One share of Esperion Therapeutics stock can currently be purchased for approximately $46.86.


MarketBeat Community Rating for Esperion Therapeutics (NASDAQ ESPR)
Community Ranking:  2.6 out of 5 ( )
Outperform Votes:  253 (Vote Outperform)
Underperform Votes:  230 (Vote Underperform)
Total Votes:  483
MarketBeat's community ratings are surveys of what our community members think about Esperion Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Esperion Therapeutics (NASDAQ:ESPR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Hold Ratings, 4 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.55)
Consensus Price Target: $40.95 (12.61% downside)

Analysts' Ratings History for Esperion Therapeutics (NASDAQ:ESPR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/10/2017Jefferies Group LLCInitiated CoverageHold -> Hold$55.00LowView Rating Details
6/26/2017Stifel NicolausReiterated RatingBuy -> Buy$45.00 -> $60.00LowView Rating Details
6/23/2017Deutsche Bank AGInitiated CoverageBuy$48.00HighView Rating Details
6/22/2017Citigroup Inc.Reiterated RatingBuyHighView Rating Details
3/20/2017J P Morgan Chase & CoReiterated RatingHold$22.00 -> $50.00MediumView Rating Details
3/20/2017Royal Bank Of CanadaReiterated RatingHold$45.00HighView Rating Details
3/20/2017Needham & Company LLCBoost Price TargetStrong-Buy -> Strong-Buy$25.00 -> $58.00HighView Rating Details
3/20/2017Credit Suisse GroupUpgradeUnderperform -> Neutral$29.00HighView Rating Details
11/6/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
10/15/2016Chardan CapitalReiterated RatingNeutral$12.50N/AView Rating Details
8/31/2016Barclays PLCSet Price TargetHold$13.00N/AView Rating Details
7/5/2016WallachBeth CapitalDowngradeBuy -> Hold$35.00N/AView Rating Details
6/29/2016Lake Street CapitalLower Price TargetBuy$80.00 -> $27.00N/AView Rating Details
11/6/2015Bank of America CorporationReiterated RatingBuy$65.00N/AView Rating Details
8/17/2015FIXReiterated RatingaddN/AView Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for Esperion Therapeutics (NASDAQ:ESPR)
Earnings by Quarter for Esperion Therapeutics (NASDAQ:ESPR)
Earnings History by Quarter for Esperion Therapeutics (NASDAQ ESPR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2017Q1 2017($1.44)($1.80)ViewN/AView Earnings Details
2/22/201712/31/2016($1.24)($1.29)ViewN/AView Earnings Details
11/3/2016Q3($0.82)($0.77)ViewN/AView Earnings Details
8/4/2016Q2($0.78)($0.62)ViewN/AView Earnings Details
5/4/2016Q116($0.74)($0.65)ViewN/AView Earnings Details
2/25/2016Q4($0.61)($0.58)ViewN/AView Earnings Details
11/5/2015Q3($0.60)($0.57)ViewN/AView Earnings Details
8/6/2015Q215($0.58)($0.55)ViewN/AView Earnings Details
5/7/2015Q115($0.54)($0.56)ViewN/AView Earnings Details
3/5/2015Q4 2014($0.54)($0.49)ViewN/AView Earnings Details
8/12/2014Q214($0.55)($0.60)ViewN/AView Earnings Details
5/12/2014Q1 2014($0.62)($0.51)ViewN/AView Earnings Details
3/5/2014($0.50)($0.63)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Esperion Therapeutics (NASDAQ:ESPR)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($1.38)($1.38)($1.38)
Q3 20171($1.40)($1.40)($1.40)
Q4 20171($1.42)($1.42)($1.42)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Esperion Therapeutics (NASDAQ:ESPR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Esperion Therapeutics (NASDAQ:ESPR)
Insider Ownership Percentage: 32.50%
Institutional Ownership Percentage: 80.50%
Insider Trades by Quarter for Esperion Therapeutics (NASDAQ:ESPR)
Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)
Insider Trades by Quarter for Esperion Therapeutics (NASDAQ:ESPR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/22/2017Dov A Md GoldsteinDirectorSell800,000$41.66$33,328,000.00View SEC Filing  
3/21/2017Gilbert S OmennDirectorBuy1,000$42.26$42,260.00View SEC Filing  
11/1/2016Narendra D LalwaniCOOBuy5,000$9.93$49,650.00View SEC Filing  
7/6/2016Mark E McgovernDirectorBuy5,000$10.00$50,000.00View SEC Filing  
5/4/2016Timothy M MaylebenCEOBuy7,000$14.85$103,950.00View SEC Filing  
3/1/2016Gilbert S OmennDirectorBuy5,000$15.28$76,400.00View SEC Filing  
1/27/2016Timothy M MaylebenCEOBuy3,600$15.88$57,168.00View SEC Filing  
1/15/2016Timothy M MaylebenCEOBuy7,200$14.08$101,376.00View SEC Filing  
4/24/2015Dov A Md GoldsteinDirectorSell217,469$108.22$23,534,495.18View SEC Filing  
11/18/2014Patrick G EnrightDirectorSell487,130$32.78$15,968,121.40View SEC Filing  
10/21/2014Parters Vii L P DomainMajor ShareholderBuy500,000$20.00$10,000,000.00View SEC Filing  
10/7/2014Longitude Capital Partners, LlMajor ShareholderSell11,927$30.04$358,287.08View SEC Filing  
7/1/2013Brian H DoveyMajor ShareholderBuy285,714$14.00$3,999,996.00View SEC Filing  
7/1/2013Daniel JanneyDirectorBuy235,714$14.00$3,299,996.00View SEC Filing  
7/1/2013Roger S NewtonChairmanBuy42,346$14.00$592,844.00View SEC Filing  
7/1/2013Timothy M MaylebenCEOBuy5,000$14.00$70,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Esperion Therapeutics (NASDAQ:ESPR)
Latest Headlines for Esperion Therapeutics (NASDAQ:ESPR)
Source:
DateHeadline
fool.com logoThe CEO Behind Lipitor Is Working on a Promising New Cholesterol Drug - Motley Fool
www.fool.com - July 26 at 6:59 PM
streetinsider.com logoEsperion Therapeutics (ESPR) Reports Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor - StreetInsider.com
www.streetinsider.com - July 26 at 6:59 PM
finance.yahoo.com logoEsperion Announces Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor
finance.yahoo.com - July 26 at 6:59 PM
finance.yahoo.com logo3 Small Biotech Stocks Being Run by Proven Winners
finance.yahoo.com - July 17 at 10:56 AM
americanbankingnews.com logoEsperion Therapeutics, Inc. (ESPR) to Post Q2 2017 Earnings of ($1.38) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - July 13 at 10:02 AM
americanbankingnews.com logoEsperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 11 at 5:34 PM
americanbankingnews.com logoEsperion Therapeutics, Inc. (ESPR) Coverage Initiated by Analysts at Jefferies Group LLC
www.americanbankingnews.com - July 10 at 5:26 PM
finance.yahoo.com logo3 Stocks That Turned $7,000 Into As Much As $37,000 So Far in 2017
finance.yahoo.com - July 8 at 10:33 AM
seekingalpha.com logoEsperion Therapeutics: Is Investor Enthusiasm Justified? - Seeking Alpha
seekingalpha.com - July 6 at 1:50 AM
thestreet.com logoBiotech Movers: Akebia Shares Down After Pricing Stock Offering - TheStreet.com
www.thestreet.com - June 30 at 6:01 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Heat Biologics Inc. and Esperion Therapeutics
finance.yahoo.com - June 29 at 7:56 PM
nasdaq.com logoHere's Why Shares of Esperion Therapeutics (ESPR) Popped Today - Nasdaq
www.nasdaq.com - June 29 at 4:51 AM
finance.yahoo.com logoHere's Why Shares of Esperion Therapeutics (ESPR) Popped Today
finance.yahoo.com - June 28 at 11:50 PM
finance.yahoo.com logoEsperion Breaks Out On Cholesterol Tie-Up With Dow's Merck
finance.yahoo.com - June 28 at 6:47 PM
nasdaq.com logoEsperion's Combo Cholesterol Candidate Enters Phase III
www.nasdaq.com - June 28 at 1:46 PM
finance.yahoo.com logoEsperion's Combo Cholesterol Candidate Enters Phase III
finance.yahoo.com - June 28 at 1:46 PM
streetinsider.com logoEsperion Therapeutics (ESPR) Reports FDA Confirmation of Regulatory Pathway to Approval for the Combination of ... - StreetInsider.com
www.streetinsider.com - June 26 at 11:04 PM
americanbankingnews.com logoEsperion Therapeutics, Inc. (ESPR) Rating Reiterated by Stifel Nicolaus
www.americanbankingnews.com - June 26 at 10:44 PM
streetinsider.com logoEsperion Therapeutics (ESPR) Reports FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid & Ezetimibe
www.streetinsider.com - June 26 at 6:02 PM
finance.yahoo.com logoEsperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and Ezetimibe
finance.yahoo.com - June 26 at 6:02 PM
americanbankingnews.com logoEsperion Therapeutics, Inc. (ESPR) Upgraded to Buy at BidaskClub
www.americanbankingnews.com - June 25 at 3:04 PM
americanbankingnews.com logoEsperion Therapeutics, Inc. (ESPR) Given Buy Rating at Citigroup Inc.
www.americanbankingnews.com - June 24 at 11:56 AM
americanbankingnews.com logoEsperion Therapeutics, Inc. (ESPR) Now Covered by Analysts at Deutsche Bank AG
www.americanbankingnews.com - June 23 at 12:12 PM
americanbankingnews.com logoComparing Spectrum Pharmaceuticals (SPPI) & Esperion Therapeutics (ESPR)
www.americanbankingnews.com - June 22 at 4:44 PM
finance.yahoo.com logoBiotechs Surge As Generalists Return Amid Subsiding Trump Woes
finance.yahoo.com - June 21 at 6:36 PM
americanbankingnews.com logoEsperion Therapeutics, Inc. (ESPR) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - June 16 at 3:04 PM
globenewswire.com logoEsperion to Present at the JMP Securities 2017 Life Sciences Conference - GlobeNewswire (press release)
globenewswire.com - June 14 at 6:13 PM
finance.yahoo.com logoEsperion to Present at the JMP Securities 2017 Life Sciences Conference
finance.yahoo.com - June 14 at 6:13 PM
finance.yahoo.com logoApple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct
finance.yahoo.com - June 9 at 5:30 PM
bloomberg.com logoRecent ALXN News
www.bloomberg.com - June 8 at 11:06 PM
americanbankingnews.com logoEsperion Therapeutics Inc (ESPR) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - June 4 at 6:46 PM
nasdaq.com logoCommit To Purchase Esperion Therapeutics At $27, Earn 21.2% Annualized Using Options - Nasdaq
www.nasdaq.com - June 1 at 5:47 PM
americanbankingnews.com logoEsperion Therapeutics Inc (ESPR) Expected to Post Earnings of -$1.73 Per Share
www.americanbankingnews.com - May 30 at 7:38 AM
americanbankingnews.com logoEsperion Therapeutics Inc (ESPR) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 22 at 2:17 PM
finance.yahoo.com logoEsperion Provides Update on Common Stock Trading Activity
finance.yahoo.com - May 22 at 11:42 AM
seekingalpha.com logoEsperion Therapeutics: Up, Up, And Away? - Seeking Alpha
seekingalpha.com - May 19 at 9:51 PM
finance.yahoo.com logoEsperion to Participate in Fireside Chat at the UBS Global Healthcare Conference
finance.yahoo.com - May 19 at 4:49 PM
finance.yahoo.com logoEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - May 19 at 5:19 AM
finance.yahoo.com logoEsperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2017 Healthcare Conference
finance.yahoo.com - May 12 at 5:34 PM
americanbankingnews.com logoEsperion Therapeutics Inc (ESPR) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - May 9 at 7:30 PM
finance.yahoo.com logoToday's Research Report on Biotech Stocks to Watch: Immunomedics and Esperion Therapeutics
finance.yahoo.com - May 8 at 9:08 AM
finance.yahoo.com logoWhy Esperion Therapeutics Shares Were Flat In April
finance.yahoo.com - May 6 at 10:37 AM
finance.yahoo.com logoEsperion Therapeutics reports 1Q loss
finance.yahoo.com - May 5 at 5:16 PM
finance.yahoo.com logoEsperion Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 4 at 5:11 PM
americanbankingnews.com logoZacks: Analysts Anticipate Esperion Therapeutics Inc (ESPR) Will Announce Earnings of -$1.48 Per Share
www.americanbankingnews.com - May 4 at 1:26 PM
americanbankingnews.com logoEsperion Therapeutics (ESPR) Receiving Somewhat Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - May 2 at 9:52 AM
americanbankingnews.com logoEsperion Therapeutics Inc (ESPR) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 1 at 9:30 PM
americanbankingnews.com logoSomewhat Favorable Press Coverage Extremely Likely to Impact Esperion Therapeutics (ESPR) Stock Price
www.americanbankingnews.com - April 29 at 12:53 PM
americanbankingnews.com logoEsperion Therapeutics Inc (ESPR) to Release Earnings on Monday
www.americanbankingnews.com - April 29 at 7:09 AM
americanbankingnews.com logoEsperion Therapeutics (ESPR) Receives Daily Coverage Optimism Score of 0.20
www.americanbankingnews.com - April 27 at 1:11 AM

Social

Chart

Esperion Therapeutics (ESPR) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff